LAG3 and metastatic melanoma: Relatlimab, a LAG-3-directed monoclonal antibody, is the first LAG-3 inhibitor approved in combination with nivolumab by the FDA for the treatment of previously untreated unresectable or metastatic melanoma based on the results of the RELATIVITY-047 trial [100].